Trial Profile
Phase IIa study of pharmacokinetics and pharmacodynamics, to confirm the inhibitory effect of temsirolimus on the mTOR pathway in endometrial cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Endometrial cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms POEM
- 13 Apr 2015 According to the ClinicalTrials.gov record, status changed from recruiting to completed.
- 24 Apr 2012 New trial record